|1.11|| +0.04 / +3.74%|
Bio-Path Holdings, Inc. operates as a holding company, which through its subsidiary Bio-Path, Inc. develops novel cancer therapeutic products. It is licensed for developing three lead products and nucleric acid delivery technology, including tumor targeting technology. The company's lead product candidate, Liposomal Grb-2, is a liposomal antisense drug and is in a Phase I study for blood cancers. Its second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors. Bio-Path Holdings was founded by Peter Nielsen, Gabriel Lopez-Berestein and Ana Maria Tari in May 2007 and is headquartered in Houston, TX.
|Peter H. Nielsen||Chairman, President, CEO, CFO, Treasurer & PAO|
|Ulrich W. Mueller||Chief Operating Officer|
|Ana Maria Tari||Director-Preclinical Operations & Research|
|Tara Sadeghi||Director-Clinical Operations|